November 16, 2016 - By Marie Mckinney · 0 Comments
Glycomimetics Inc (NASDAQ:GLYC) institutional sentiment increased to 6.17 in 2016 Q2. Its up 5.26, from 0.91 in 2016Q1. The ratio is better, as 37 active investment managers increased or opened new positions, while 6 decreased and sold stakes in Glycomimetics Inc. The active investment managers in our partner’s database now possess: 36.68 million shares, up from 13.85 million shares in 2016Q1. Also, the number of active investment managers holding Glycomimetics Inc in their top 10 positions increased from 1 to 2 for an increase of 1. Sold All: 2 Reduced: 4 Increased: 15 New Position: 22.
GlycoMimetics, Inc. is a clinical-stage biotechnology company. The company has a market cap of $142.71 million. The Firm focuses on the discovery and development of glycomimetic drugs. It currently has negative earnings. The Firm operates through the identification and development of glycomimetic compounds segment.
About 897 shares traded hands. GlycoMimetics Inc (NASDAQ:GLYC) has risen 4.65% since April 14, 2016 and is uptrending. It has underperformed by 0.03% the S&P500.
According to Zacks Investment Research, “GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States.”
Bvf Inc Il holds 3.79% of its portfolio in GlycoMimetics Inc for 2.45 million shares. Nea Management Company Llc owns 8.58 million shares or 3.24% of their US portfolio. Moreover, Sphera Funds Management Ltd. has 1.36% invested in the company for 718,080 shares. The California-based Wall Street Associates has invested 0.44% in the stock. Cormorant Asset Management Llc, a Massachusetts-based fund reported 287,031 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 insider purchases, and 3 insider sales for $197,955 net activity.
Ratings analysis reveals 100% of GlycoMimetics’s analysts are positive. Out of 2 Wall Street analysts rating GlycoMimetics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. GLYC was included in 3 notes of analysts from August 10, 2015. SunTrust initiated the shares of GLYC in a report on Tuesday, July 26 with “Buy” rating. As per Monday, August 10, the company rating was upgraded by Zacks. The firm earned “Outperform” rating on Monday, August 15 by Cowen & Co.
GlycoMimetics, Inc., incorporated on April 4, 2003, is a clinical-stage biotechnology company. The Firm focuses on the discovery and development of glycomimetic drugs. The Firm operates through the identification and development of glycomimetic compounds segment. The Firm is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Firm is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and potentially other hematologic cancers. The Firm has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. GMI-1359 is undergoing testing in preclinical models from which it intends to select a target clinical indication, in oncology. The Firm is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9, which have potential to be used for the treatment of fibrosis, cancer and cardiovascular disease.
More recent GlycoMimetics Inc (NASDAQ:GLYC) news were published by: Quotes.Wsj.com which released: “GlycoMimetics Inc. GLYC (US: Nasdaq)” on November 02, 2013. Also Businesswire.com published the news titled: “GlycoMimetics, Inc. Announces Initiation of First Clinical Trial Evaluating …” on October 29, 2015. Businesswire.com‘s news article titled: “GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation …” with publication date: June 23, 2015 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marie Mckinney